Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas

Lymphoma

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study

Eur J Cancer

Fabbri N, Casadei B, Chiappella A, Stella F, Donzelli L, Galli E, Riva M, Martino M, Barbui AM, Musso M, Farina M, Angelillo P, Cutini I, Santoro A, Cavallo F, Rivela P, Castellino A, Krampera M, Petruzzellis G, Grillo G, Argnani L, Bonifazi F, Corradini P, Zinzani PL

doi: 10.1016/j.ejca.2026.116879

Multiple Myeloma (MM)

B-cell maturation antigen-targeted CAR T cell as a salvage therapy for progressive multiple myeloma after anti-G proteincoupled receptor, class C group 5 member D CAR T-cell therapy

Haematologica

Zhang X, Xia F, Qi K, Xia J, Zhou D, Sun Q, Zhang H, Wang X, Sang W, Li D, Yan Z, Chang AH, Cao J, Pan B

doi: 10.3324/haematol.2026.301282

Lymphoma

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study

Lancet Haematol

Efficace F, Zinzani PL, Bonifazi F, Cutini I, Botto B, Chiappella A, Tisi MC, Bramanti S, Puglia S, Tartaglia F, Donzelli L, Farina M, Martino M, Gambella M, Ragaini S, Orciuolo E, Martelli M, Corradini P, Fazi P, Vignetti M, Rocco AD

doi: 10.1016/S2352-3026(26)00128-6

Lymphoma

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting

Br J Haematol

Villeneuve PJA, Mozessohn L, Somé NH, Mercer RE, Masucci L, Kouroukis T, Bredeson C, Aktar S, Guan Q, Prica A, Chen CI, Rodin D, Cheung M, Chaudhry M, Gavura S, McKay C, Wong WWL, Chan KKW

doi: 10.1111/bjh.70632

Lymphoma

CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study

Haematologica

Magni M, Jonnalagadda S, Bonifazi F, Bonafe M, Ljevar S, Zanirato G, De Matteis S, Stella F, Barone A, Bertolini G, Bermema A, Chiappella A, Tisi MC, Cutini I, Novo M, Grillo G, Farina M, Martino M, Krampera M, Massaia M, Arcaini L, Bramanti S, Zinzani PL, Dodero A, Corradini P, Carniti C

doi: 10.3324/haematol.2025.287528

ASH 2025

Lymphoma

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

Lymphoma

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol

Br J Haematol

Mikhaeel NG, Bouziana S, Northend M, Brady JL, Sanderson R, Sivabalasingham S, Springell D, Roddie C, Bourlon C, Farias MC, Davila AM, Benjamin R, Patten PEM, Kumar E, Yallop D, Hwang A, Kamat S, Ntentas G, Kuhnl A

doi: 10.1111/bjh.70653

Lymphoma

Different treatment eras for relapsed and refractory primary mediastinal B-cell lymphoma patients: accessibility to CAR T cells is associated with a better prognosis in a pooled analysis of the REPRIME-FIL and the CART-SIE studies

Haematologica

Guidetti A, Dogliotti I, Chiappella A, Iannitto E, Evangelista A, Dodero A, Di Rocco A, Balzarotti M, Casadei B, Cavallo F, Re A, Farina M, Bramanti S, Chiusolo P, Martino M, Musso M, Zanni M, Grillo G, Ravano E, Krampera M, Hohaus S, Martelli M, Zacchi G, Visco C, Zinzani PL, Consoli U, Corradini P

doi: 10.3324/haematol.2026.300977

Lymphoma

The impact of radiotherapy on the therapeutic response of patients treated with CAR T-cell therapy for high-grade lymphoma: a systematic review

Leuk Lymphoma

Belghoul M, Kuhnl A, Chevassut T, Sanderson R, Mikhaeel G, Benjamin R, Patton P, Jones J

doi: 10.1080/10428194.2026.2685253

Related content

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study

B-cell maturation antigen-targeted CAR T cell as a salvage therapy for progressive multiple myeloma after anti-G proteincoupled receptor, class C group 5 member D CAR T-cell therapy

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting

CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol

Different treatment eras for relapsed and refractory primary mediastinal B-cell lymphoma patients: accessibility to CAR T cells is associated with a better prognosis in a pooled analysis of the REPRIME-FIL and the CART-SIE studies

The impact of radiotherapy on the therapeutic response of patients treated with CAR T-cell therapy for high-grade lymphoma: a systematic review